drugset / Trial / NCT01996839

Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT01996839

Phase 3 Completed 514 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel

Timeline

Start
2013-12
Primary completion
2014-05
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Loteprednol Etabonate Other / unclassified Topical

Indications